Highlights
- BCR::ABL1 tyrosine kinase inhibitors (TKIs) induce nuclease-resistant ribosome collisions in chronic myeloid leukemia (CML) cells.
- The kinase ZAK serves as a molecular sensor of these collisions, initiating the ribotoxic stress response (RSR) and p38-mediated apoptosis.
- ZAK expression increases as CML progresses from chronic phase to blast phase, where it sustains proliferation through AKT signaling but sensitizes cells to TKI-induced death.
- Targeting the translational and metabolic machinery—including the mTOR-EEF2K axis and mitochondrial OXPHOS—presents new opportunities to overcome TKI resistance.
Background
Specialty calculators
For clinical reference; use professional judgment.
